Product image of Methylphenidate Orifarm (Methylphenidate Hydrochloride) supplied by GNH India

Methylphenidate Orifarm

Active Ingredient:
Methylphenidate Hydrochloride
Origin:
EU

Methylphenidate Orifarm (Methylphenidate Hydrochloride)

Methylphenidate, the active ingredient in Methylphenidate Orifarm, is a central nervous system stimulant presented as an oral dosage form for oral use. It works by increasing the concentrations of dopamine and norepinephrine in the brain and is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in children, adolescents and adults.

GNH India supplies Methylphenidate Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets, and reliable delivery.

Manufacturer / TM Owner

Orifarm Generics A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methylphenidate Orifarm is a central nervous system stimulant used in disorders that involve attention regulation and wakefulness.

  • Attention deficit hyperactivity disorder (ADHD) in children and adolescents: enhances focus and reduces hyperactive behavior.
  • Attention deficit hyperactivity disorder (ADHD) in adults: supports sustained attention and impulse control.
  • Narcolepsy: lessens excessive daytime sleepiness and reduces cataplexy.

How It Works

  • Methylphenidate blocks the reuptake transporters for dopamine and norepinephrine in neuronal synapses, leading to increased extracellular concentrations of these catecholamines. By inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), methylphenidate prolongs the signaling duration of these neurotransmitters, thereby normalizing the deficient pathways observed in ADHD and narcolepsy.

Side Effects

Methylphenidate Orifarm may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Insomnia: difficulty falling or staying asleep.
  • Loss of appetite: reduced hunger leading to weight loss.
  • Headache: mild to moderate cranial pain.
  • Stomach upset: nausea, abdominal discomfort.
  • Increased heart rate: mild tachycardia.
  • Irritability: mood changes or agitation.

Serious or Rare Side Effects

  • Cardiovascular events: chest pain, hypertension, arrhythmia.
  • Psychiatric symptoms: psychosis, severe anxiety, mood swings.
  • Growth suppression: reduced growth velocity in children.
  • Allergic reactions: rash, itching, swelling, anaphylaxis.

Precautions & Warnings

When prescribing Methylphenidate Orifarm, clinicians should consider several precautionary measures to ensure safe use.

  • Cardiovascular assessment: evaluate blood pressure and heart history before initiation.
  • Psychiatric evaluation: screen for history of psychosis, bipolar disorder, or severe anxiety.
  • Monitor growth: regularly assess height and weight in pediatric patients.
  • Drug dependence: avoid use in individuals with a history of substance abuse.
  • Concomitant medications: review for agents that may increase cardiovascular risk.
  • Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Avoid Interactions

Methylphenidate Orifarm can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis; avoid concurrent use.
  • Tricyclic antidepressants: may increase cardiovascular side effects.
  • Antihypertensive agents: can reduce blood pressure‑lowering effect.

Moderate Interactions (Monitor Closely)

  • CYP2D6 inhibitors (e.g., fluoxetine): may raise methylphenidate plasma levels.
  • Antacids: may affect absorption, monitor therapeutic response.
  • Seizure threshold‑lowering drugs: increased risk of seizures, observe closely.

Frequently Asked Questions

Methylphenidate Orifarm is prescribed to manage attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults, and to treat narcolepsy by reducing excessive daytime sleepiness and cataplexy. It belongs to the class of central nervous system stimulants that improve focus, impulse control, and wakefulness.

Methylphenidate inhibits the reuptake of dopamine and norepinephrine at neuronal synapses, increasing their extracellular levels. This heightened catecholamine activity in the prefrontal cortex and related brain regions enhances neurotransmission involved in attention, executive function, and arousal, thereby alleviating symptoms of ADHD and narcolepsy.

The appropriate dose of Methylphenidate Orifarm is individualized by the prescribing clinician based on the patient’s age, weight, severity of symptoms, and response to therapy. Dosage adjustments are made according to clinical effectiveness and tolerability, following local prescribing guidelines.

Safety data for methylphenidate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers typically advise women to discuss alternative treatments and to avoid breastfeeding while on the medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Methylphenidate Orifarm is a short‑acting stimulant, whereas alternatives such as amphetamine‑based products or non‑stimulant agents (e.g., atomoxetine) have different pharmacologic profiles, durations of action, and side‑effect spectra. Choice of therapy depends on individual response, comorbid conditions, and physician assessment.

Store Methylphenidate Orifarm at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, heat and direct light, and ensure the container is tightly closed to maintain stability.

Methylphenidate Orifarm is taken orally, usually with or without food, as directed by the prescribing clinician. The tablet (or other oral form) should be swallowed whole and not crushed or chewed unless specifically instructed.

Serious adverse events include cardiovascular complications such as hypertension, chest pain, or arrhythmia, as well as psychiatric effects like psychosis, severe anxiety, or mood disturbances. Any sudden chest pain, severe headache, or behavioral changes should prompt immediate medical evaluation.

Methylphenidate Orifarm is contraindicated in individuals with known hypersensitivity to methylphenidate, those who have taken monoamine oxidase inhibitors within the past 14 days, and patients with severe cardiovascular disease, uncontrolled hypertension, or a history of psychosis without careful supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methylphenidate Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT